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Abstract
Background: The aim was to test the primary hypothesis that in patients suffering from shock, treatment with
N-acetylcysteine (NAC) plus deferoxamine (DFX) decreases the incidence of acute kidney injury (AKI).
Methods: A double-blind, randomized, placebo-controlled trial was conducted in a general intensive care unit in
an academic hospital. Patients were included if they had new-onset hypotension, defined as mean arterial blood
pressure <60 mmHg or requirement for vasopressor medication. A loading dose of NAC or placebo of 50 mg/kg in
4 h was administered intravenously. After the loading dose, patients received 100 mg/kg/day for the next 48 h. DFX
or placebo was administered once at 1000 mg at a rate of 15/mg/kg/h. The primary outcome was the incidence of AKI.
Results: A total of 80 patients were enrolled in the study. The incidence of AKI was 67 % in the placebo arm and 65 % in
the treatment group (relative risk (RR) 0.89 (0.35–2.2)). Furthermore, NAC plus DFX was effective in decreasing the severity
and duration of AKI, and patients in the treatment group had lower serum creatinine levels at discharge. No severe adverse
event associated with treatment was reported. The effects of NAC plus DFX could be secondary to the attenuation of early
inflammatory response and oxidative damage.
Conclusion: The administration of NAC plus DFX to critically ill patients who had a new episode of hypotension did not
decrease the incidence of AKI.
Trial registration: Clinicaltrials.gov NCT00870883 (Registered 25 March 2009.)
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Background
Oxidative stress and inflammation are related events and
occur in a variety of illnesses, including critical illness
[1]. Both oxidative damage and inflammatory biomarkers
are associated with experimental and clinical kidney in-
jury [2–5], and are independently associated with worse
outcomes in patients with shock [6, 7]. These processes
may mediate poor clinical outcomes through endothelial
damage, oxidation of lipid membranes and proteins,
nitric oxide scavenging and vasoconstriction, and cell
apoptosis, and all these factors can be associated with
the development of acute kidney injury (AKI) [8, 9].
In this context antioxidants could have therapeutic
value to prevent AKI in the critically ill patient. N-acet-
ylcysteine (NAC) scavenges oxidant species and donates
sulfhydryl groups to the synthesis of glutathione. In ani-
mal studies, NAC attenuates oxidative damage and kid-
ney injury caused by shock [10]. In patients with shock,
NAC administration prevents oxidative damage and can
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attenuate some markers of disease severity [11], but its
protective effect is controversial [12]. However, NAC has
some limitations when used as an antioxidant. Larger
doses of NAC can have oxidant effects, probably because
it interacts with iron [13]. This may also account for
some of the negative results in clinical trials of NAC. In
this context, we and others have demonstrated that the
addition of an iron chelator (deferoxamine - DFX) to
NAC treatment improves its protective effects [14–18].
In a pilot trial we demonstrated that NAC plus DFX de-
crease plasma levels of both oxidative and inflammatory
parameters in patients with shock [19].
On the basis of these data we conducted a random-
ized, double-blind, placebo-controlled, parallel-group
trial to test the hypothesis that treatment with NAC plus
DFX is superior to placebo to improve renal function in
patients with shock. We further hypothesized that the
protective effect of these drugs could be related to its
antioxidant and anti-inflammatory effects.
Methods
Patients
Patients were enrolled in the São José Hospital intensive
care unit (ICU), Criciúma, Brazil. The trial was approved
by the São José Hospital Institutional Review Board and
was registered on www.clinicaltrials.gov (NCT00870883).
Written informed consent was obtained from all patients
or their surrogates. A safety monitor board reviewed all
adverse events. All the procedures were in accordance
with the Declaration of Helsinki. The trial was conducted
in accordance to the original protocol, and the full proto-
col can be accessed on request.
The same inclusion and exclusion criteria as were used
in the NEPHRON clinical trial [20] were adopted to
allow indirect comparison with another study in which
NAC was used. Patients were included if they had new
onset of 30 consecutive minutes of hypotension, defined
as mean arterial blood pressure <60 mmHg that did not
improve after fluid infusion or requirement for vasopres-
sor medication (dopamine drip at 10 μg/kg/min or
norephinephrine, ephinephrine, or vasopressin drip at
any concentration). Patients who had an episode of
hypotension within the previous 48 h were excluded.
The first dose of NAC plus DFX, or placebo, had to be
given within 12 h of meeting the inclusion criteria.
Patients were excluded if they met any of the following
exclusion criteria: age <18 years, participating in another
research study, allergy to NAC or DFX, received high-
dose NAC for acetaminophen overdose in the previous
48 h, pregnant or lactating, received activated charcoal
in the previous 48 h, serum creatinine >3.5 mg/dL or
already on hemodialysis, patients with hemoglobin
<6.5 mg/dl, weight <40 kg, advanced malignancy, or a
“do not resuscitate” order.
A research nurse generated the allocation sequence in
a ratio of 1:1, based on a simple randomization scheme
(http://graphpad.com/quickcalcs/randomize1). The same
nurse assigned participants to study groups, and after in-
formed consent was obtained enrolled patients to receive
NAC plus DFX, or placebo. Both placebo and treatment
solutions were prepared and infused by the research
nurse, the only person to know the group allocation; the
patients, intensive care team, and researchers were
blinded to group allocation. The appearance of the flasks
containing the treatment or placebo was the same. As
NAC has a peculiar smell, after the infusion the research
nurse discharged the flasks outside the ICU to try and
maintain the masking of the treatment arm.
A loading dose of 50 mg/kg NAC diluted in 250 mL of
glucose 5 % was administered intravenously at an infu-
sion rate of 62.5 ml/h. After the loading dose, patients
received a continuous infusion of NAC 100 mg/kg/day
diluted in 250 mL glucose 5 % for two consecutive days.
DFX was administered once at a dose of 1000 mg dis-
solved in 250 mL glucose 5 % at a rate of 3.75 mL/kg/h.
The placebo group received the same volume and pro-
cedural infusion of glucose 5 %.
Data collection
After entry into the study, demographic information was
collected for each patient. Preexisting medical problems
were recorded and the Charlson comorbidity score was
calculated. The patient’s baseline creatinine for the study
was the most recent measurement of creatinine before
entry into the study. The Acute Physiology and Chronic
Health Evaluation (APACHE) II score was computed for
the 24-h period before study inclusion. Sequential Organ
Failure Assessment (SOFA) scores were computed
during the first 3 days after inclusion. Sepsis was defined
according to internationally agreed criteria [21]. Cardio-
genic shock was defined by persistent hypotension, and
poor perfusion with reduction in cardiac index and ad-
equate or elevated filling pressure. Doppler echocardiog-
raphy was used in patients without a pulmonary artery
catheter, to determine whether shock was of cardiac origin.
For the duration of the ICU hospitalization, serum cre-
atinine (SCr) and urine output was recorded daily, and
from this information the incidence of AKI was defined
as a new or worsening AKI stage as suggested by the
Kidney Disease Improving Global Outcomes (KIDGO)
Guideline for Acute Kidney Injury [22], and was the pri-
mary study outcome. Several secondary outcomes were
examined including the severity of AKI (stages 2 and 3
defined according to the KIDGO Guideline for Acute
Kidney Injury), number of days with AKI, time to devel-
opment of the first episode of AKI, SOFA score at day 3,
SCr levels at discharge defined as the last creatinine level
before hospital discharge, ICU and hospital length of
Fraga et al. Critical Care  (2016) 20:331 Page 2 of 8
stay, and requirement for renal replacement therapy
(RRT) and mortality.
Inflammatory and oxidative damage parameters
Blood was collected on enrollment and 24 and 48 h
after. Blood samples were placed on ice and processed
within 10 minutes of collection by centrifugation at
3000 rpm for 10 minutes at 4 °C, and then plasma was
stored at –80 °C. Plasma interleukin (IL)-6, IL-10, IL-8,
thiobarbituric acid reactive species (TBARS) and protein
carbonyls were measured in singulate. Interleukins were
measured using commercial ELISA kits (R&D System),
and were expressed as pg/mL plasma. The determination
of carbonyl groups in proteins provides a convenient tech-
nique to detect and quantify oxidative modification in
proteins. The method for determination of carbonyl con-
tent used was based on the reaction of carbonyl groups
with 2,4-dinitrophenylhydrazine to form a 2,4-dinitrophe-
nylhydrazonedetected at 280 nm. Protein carbonyls levels
were expressed as nmol/mL plasma. As evidence of oxida-
tive damage the formation of malondialdehyde (MDA) −
thiobarbituric acid complex was assessed using the
TBARS reaction. The amount of TBARS was deter-
mined by measuring the absorbance at 532 nm.
TBARS concentration was expressed as MDA equiva-
lents (nmol)/mL plasma).
Statistical analysis
The expected incidence of AKI incidence was 60 % and
the expected absolute risk reduction was 20 %; thus, it
was determined that 70 patients would need to be en-
rolled in each arm to have 80 % power to detect this dif-
ference using a two-sided test at a significance level 0.05.
However, the enrollment rate was slower than expected.
In May of 2015, 80 patients had been enrolled, and the
data and safety monitoring board recommended stop-
ping enrollment at this time.
All analyses were performed according to the
intention-to-treat principle. The primary outcome was
analyzed using the chi-square test. Continuous second-
ary outcomes were analyzed by Student’s t test or Mann-
Whitney U test, depending on the data distribution.
Dichotomous secondary outcomes were assessed using
the chi-square test. Variables that could confound the
effect of treatment upon the outcomes were entered into
forward multivariate logistic regression analysis. Thus, as
prespecified, a model was created that included treat-
ment group, age, SOFA score at enrollment and sepsis.
The Hosmer–Lemeshow goodness-of-fit test was used
to evaluate the agreement between the observed and ex-
pected outcome. The area under the receiver-operating
characteristic curve (AROC) was used to assess the
model discrimination. A linear mixed model was used to
determine the effect of treatment on the temporal
variations of biomarker levels. Statistical significance was
defined as a p value <0.05.
Results
A total of 382 patients were assessed for eligibility from
February 2012 to May 2015, of whom 80 were enrolled
in the study (Fig. 1). Baseline data were similar among
the study groups (Table 1). There was no early termin-
ation of the treatment protocol. The ICU team did not
report any severe adverse events associated with treat-
ment. On statistical analysis there was no significant
effect of NAC plus DFX on the incidence of AKI
(Table 2). Only 4 patients (10 %) in the placebo group,
and 5 (12.5 %) in the NAC plus DFX group had AKI
defined based on SCr levels. The vast majority were cat-
egorized as AKI on the basis of urine output or urine
output plus SCr criteria. Only age and SOFA at study
admission were independently associated with the inci-
dence of AKI in our sample. When secondary outcomes
were analyzed, NAC plus DFX was effective in decreas-
ing the severity and duration of AKI, and patients in the
treatment group had lower SCr at discharge. No other
significant differences were observed (Tables 2 and 3).
The effects of NAC plus DFX could be secondary to
the attenuation of early inflammatory response and oxi-
dative damage. Baseline inflammatory and oxidative
damage parameters were similar between groups. Both
TBARS and IL-6 increased after allocation in the pla-
cebo group (Fig. 2a and b). However, NAC plus DFX
treatment reversed this trend. In addition, NAC plus
DFX, but not placebo, decreased IL-8 (Fig. 2c). There
was no significant effect of NAC plus DFX treatment on
IL-10 and protein carbonyls (Fig. 2d and e).
Discussion
We have demonstrated that the incidence of AKI did
not decrease after treatment with NAC plus DFX in
patients with new onset of sustained hypotension. How-
ever, there was a significant difference in the severity of
AKI and patients in the treatment group had lower SCr
at discharge. In addition, NAC plus DFX treatment
decreased blood oxidative and inflammatory parameters.
Oxidative damage can be detected in plasma in a num-
ber of critical illnesses, such as sepsis (6), acute respiratory
distress syndrome (ARDS) [23], and hemorrhagic shock
[24]. In all of these conditions, oxidative damage has been
associated with poor clinical outcomes. Despite this, anti-
oxidant strategies aimed at improving clinically significant
outcomes give controversial results [11, 12]. To date,
NAC is one of the most common antioxidant strategy that
has been studied in critically ill patients. The inconsistency
of results using NAC could be secondary to the range of
dosing across the studies. No optimal dose for any indica-
tion has been established.
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Prophylaxis for contrast-induced nephropathy doses
ranges from 1200 to 2400 mg/day, and patients with
acetaminophen overdose require up to 1000 mg/kg.
Komisarof and colleagues studied a population similar
our treated patients, and administered an oral loading
dose of 3000 mg, followed by 4500 mg/day for the next
3 days and 2400 mg/day for the last 4 days [22]. We
used a loading intravenous dose of 3500 mg (for a pa-
tient weighing 70 kg), followed by a continuous infusion
of 14,000 mg (for a patient weighing 70 kg) in the next
Flow Diagram
Fig. 1 Screening, randomization, and follow up





Age, years, mean ± SD 56 ± 14 51 ± 16
Male sex, n (%) 23 (57) 20 (50)
Charlson comorbidity score, mean ± SD 2.4 ± 2.1 2.6 ± 2.3
Medical admission, n (%) 33 (82) 32 (80)
Sepsis at enrollment, n (%) 20 (50) 21 (52)
Cardiogenic shock, n (%) 10 (25) 9 (22)
Trauma, n (%) 6 (15) 7 (17)
APACHE II score, mean ± SD 19 ± 7 20 ± 7
SOFA score day 1, mean ± SD 9.4 ± 4 9.3 ± 3.7
Creatinine at enrollment, mean ± SD 1.0 ± 0.6 1.2 ± 1.7
AKI at admission, yes, n (%) 14 (35) 12 (30)
Mechanical ventilation at enrolment, yes, n (%) 25 (62) 23 (58)
Need for vasoactive drug, yes, n (%) 34 (85) 35 (87)
NAC + DFX N-acetylcysteine plus deferoxamine, AKI acute kidney injury, APACHE
II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ
Failure Assessment, SD standard deviation











AKI incidence 27 (67) 26 (65) 0.89 (0.35–2.2) 1.1 (0.37–3.2)
AKI severity, stages 2
and 3, n (%)
24 (60) 15 (37) 0.4 (0.16–0.98) 0.35 (0.13–0.93)
RRT, n (%) 6 (15) 6 (15) 1.0 (0.29–3.4) 1.1 (0.3–4.2)
ICU death, n (%) 21 (52) 23 (57) 1.22 (0.50–2.9) 1.6 (0.58–4.4)
Hospital death, n (%) 23 (57) 24 (60) 1.1 (0.45–2.7) 1.3 (0.51–3.7)
NAC + DFX N-acetylcysteine plus deferoxamine, AKI acute kidney injury, RRT
renal replacement therapy, ICU intensive care unit
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2 days, which is higher than in the Komisarof study, and
the route of administration was also different (oral as
compared to intravenous). Thus, it is difficult to directly
compare different studies. We chose this dose because it
is similar to the dose used in our pre-clinical model
(equivalent to 6–8 g/day) [14, 15]. In addition, the study
of Komisarof and colleagues suggests that higher doses
must be used in the context of hypotension [20]: they
observed a trend towards a lower SOFA score during
the first 3 days of NAC administration, but this trend
disappeared shortly after the reduction of the NAC dose
[20]. It is unknown whether higher doses, such as the
doses used for acetaminophen intoxication, would result
in better outcomes, mainly with the concomitant admin-
istration of DFX.
The timing of NAC therapy may also be relevant.
When administered 24 h after admission, NAC could
worsen organ dysfunction [12]. We used the same ap-
proach of Komisarof and colleagues, giving NAC plus
DFX within 12 h of the occurrence of hypotension. We
had previously demonstrated that NAC plus DFX was
effective in an animal model of sepsis when administered
3 h after induction of sepsis [14]. The protective effect
was lost when administered 12 h after induction of sep-
sis (unpublished data). As oxidative stress results in
chain reactions that could amplify the initiation reaction,
it is reasonable to suppose that interventions aimed at
decreasing oxidative damage should have its greater
effect early after initiation of disease. This narrow thera-
peutic window, allied with the higher NAC dose, and the
addition of DFX could explain our partially positive
results. In addition, this would impact on inflammatory
response, and both antioxidant and anti-inflammatory
effects could partially explain some of the protective ef-
fects of NAC +DFX. However, the effects of NAC +DFX
upon these biomarkers could alternatively reflect less se-
vere kidney injury, as some of these are cleared by the
kidney [25].
Our findings are consistent with results from pre-
clinical models, whereby we and others demonstrated
that the association of NAC plus DFX was superior to
decrease inflammation, oxidative stress and organ failure
when compared to the isolated use of NAC [14–18].
During states of shock, iron could be released from sev-
eral different sources, and free iron could drive free rad-
ical formation trough the Fenton reaction [26], besides
having several other detrimental effects [27, 28]. In
addition, NAC could have pro-oxidant effects in the
presence of iron [13]. Thus, it seems rational to add an
iron chelator to improve the antioxidant and protective
effects of NAC. We used the iron chelator as a single
dose as it has been previously in pre-clinical studies
[14–18]. This points to a major role for NAC in this
context, but as NAC has a potential pro-oxidant effect,
the addition of DFX seems to be relevant. Moving from
bench to bedside a single dose of DFX was maintained
with the theoretical objective of decreasing the pro-
oxidant effect mainly of the loading dose of NAC and
narrowing the possibility of adverse effects of DFX ad-
ministration in critically ill patients.
Iron seems to have a pivotal role in injury, specifically
in the kidney. Preloading animals with iron has been
shown to worsen ischemic damage to the kidney [29],
and the use of iron chelators is effective in different
animal models of kidney injury [30, 31]. Iron could
have direct toxic effects in the kidney, such as in-
creased vascular resistance, and direct damage to
tubular cells. One of the most relevant examples of
the role of iron in kidney damage is neutrophil
gelatinase-associated lipocalin (NGAL) [32]. NGAL is
highly upregulated after injury, and serum or urine
NGAL can be used as an early marker of kidney in-
jury in humans [33, 34]. NGAL scavenges iron ions,
and the protective effects of NGAL administration in
animal models of kidney injury seem to involve this
function [35–37].
This study has some limitations. First, this was a
single-center study. Second, our small sample size
resulted in less robust results because small changes in
the number of events or non-events would have pro-
duced different results [38]; for this reason a larger trial
will be needed to confirm these results. The narrow time
window to the administration of the drugs could restrict
its clinical use, and restricts the inclusion of several pa-
tients in our trial (patients otherwise eligible, but unable
to obtain consent and start drug administration within
the first 12 h of hypotension), which could decrease its
external validity. Third, a more in depth characterization
of the patients’ volemic status at enrollment, and






Time to develop AKI, days,
median (IR)
1.5 (1–4.5) 1 (1–2) 0.53
AKI duration, days, median (IR) 0.5 (0–6) 1 (0–2) 0.04
ICU-free days to day 28,
median (IR)
18 (2–23) 15 (2–23) 0.68
Hospital length of stay, days,
median (IR)
10 (6–22) 12 (7–18) 0.58
Creatinine level at discharge,
mg/dL, median (IR)
1.1 (0.6–1.8) 0.7 (0.5–1.2) 0.05
SOFA score day 3, median (IR) 9 (4–14) 6.5 (5–10) 0.28
Renal SOFA score day 3,
median (IR)
3 (0–3) 1 (0–2.2) 0.10
NAC + DFX N-acetylcysteine plus deferoxamine, ICU intensive care unit, AKI
acute kidney injury
SOFA Sequential Organ Failure Assessment, IR interquartile range
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parameters of fluid responsiveness would help to better
understand our results, but unfortunately this information
is not consistently available to all included patients.
Fourth, to ascertain that DFX is really acting as an iron
chelator as was hypothesized, we should measure the iron
pool that can be chelated by DFX. As DFX permeates into
cells relatively slowly and does not mobilize significant
amounts of iron from transferrin it probably binds non-
transferrin-bound iron in the serum [39]. This specific
iron pool is more labile than transferrin-bound iron and
therefore is a potential catalytic iron source that is avail-
able to chelation by DFX [39].
Conclusion
The early administration of NAC and DFX to critically
ill patients with new-onset hypotension is not associated
with lower incidence of AKI, but is related to less severe
AKI and lower SCr levels at discharge. These effects at
least seem to be linked to the antioxidant and anti-
inflammatory effects of the treatment.
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Fig. 2 Oxidative and inflammatory parameters. Blood was collected on enrollment and on the morning of the subsequent 2 days for the measurement of
thiobarbituric acid reactive species (TBARS) (a), interleukin (IL)-6 (b), IL-8 (c), IL-10 (d), and protein carbonyls (e). *Different from time 0, same group. #Difference
between groups at the same time point NAC+DFX N-acetylcysteine plus deferoxamine, MDAmalondialdehyde
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